Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

Background: The protease inhibitor (PI) darunavir (DRV) has proven to be highly effective and well tolerated for HIV treatment. The DAD (Data collection on Adverse Effects of Anti-HIV Drugs) cohort showed an increased 5-year cumulative cardiovascular (CV) risk in patients given various PIs, includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Antinori, A, Rusconi, S, Gianotti, N, Bini, T, Mancusi, D, Termini, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526181/
https://www.ncbi.nlm.nih.gov/pubmed/31190745
http://dx.doi.org/10.2147/DDDT.S180981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526181/
https://www.ncbi.nlm.nih.gov/pubmed/31190745
http://dx.doi.org/10.2147/DDDT.S180981

Ejemplares similares